Q3 2026 Resmed Inc Earnings Call Transcript

Apr 30, 2026 / 08:30PM GMT

Release Date Price: $24.89

Transcript 10-Q8-K

Key Points

Positve

ResMed Inc (RMD) reported an 11% growth in headline revenue, or 8% growth on a constant currency basis, demonstrating strong financial performance.
The company achieved a 21% growth in non-GAAP earnings per share, indicating effective cost management and operational efficiency.
ResMed Inc (RMD) continues to expand its global digital health ecosystem, focusing on sleep health, breathing health, and healthcare technology delivered in the home.
The company is investing in innovative products, such as the AirTouch N30i mask, which has shown a 6% higher 90-day compliance rate compared to its silicone equivalent.
ResMed Inc (RMD) maintains a robust balance sheet with $1.7 billion in cash and a net cash position of $996 million, providing flexibility for future investments and shareholder returns.

Negative

ResMed Inc (RMD) faces challenges with component cost inflation and geopolitical uncertainties impacting supply chain logistics.
The company's Residential Care software business experienced only a 4% growth, with ongoing challenges in the senior living and long-term care verticals.
There are concerns about the profitability of the new fabric masks for traditional HME providers, potentially affecting adoption rates.
The acquisition of Noctrix Health is expected to reduce non-GAAP EPS by approximately $0.02 in Q4 FY26, indicating short-term financial impact.
ResMed Inc (RMD) is facing competitive dynamics in the US devices segment, with new product launches from competitors potentially impacting market share.

Operator

Welcome to the Q3 fiscal year 2026 ResMed earnings conference call. My name is Daryl, and I will be your operator for today's call. (Operator Instructions) Also, please note, this conference call is being recorded. (Operator Instructions)

Let me hand the call to Salli Schwartz, ResMed's Chief Investor Relations Officer.

Salli Schwartz

Resmed Inc - Chief Investor Relations Officer

Thanks, Daryl. I want to welcome our listeners to ResMed's third-quarter fiscal year 2026 earnings call. We are live webcasting this call and the replay will be available on the Investor Relations section of our corporate website later today. Our earnings press release and presentation are both available online now.

During today's call, we will discuss several non-GAAP measures that we believe provide useful information for investors. This information is not intended to be considered in isolation or as a substitute for GAAP financial information. We encourage you to review the supporting schedules in today's earnings press release to reconcile these non-GAAP

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.